PF-01367338

PF-01367338 Basic information
Product Name:PF-01367338
Synonyms:PF01367338 phosphate;Rucaparib (AG-014699,PF-01367338) phosphate;Rucaparib (AG-014699) phosphate;AG014699;RUCAPARIB PHOSPHATE;Rucaparib (phosphate)(AG-014699,PF-01367338);Rucaparib phosphate salt;Rucaparib phosphate (AG-14699, PF-01367338);CS-47
CAS:459868-92-9
MF:C19H21FN3O5P
MW:421.37
EINECS:
Product Categories:Inhibitors;Inhibitor;Amines;Aromatics;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals
Mol File:459868-92-9.mol
PF-01367338 Structure
PF-01367338 Chemical Properties
Melting point >173°C (dec.)
storage temp. Sealed in dry,Room Temperature
solubility Soluble in DMSO (up to 25 mg/ml).
form Yellow solid.
color Yellow
Stability:Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 3 months.
Safety Information
MSDS Information
PF-01367338 Usage And Synthesis
DescriptionRucaparib phosphate (459868-92-9) is a potent (Ki<5 nM) PARP1 inhibitor.1?Cytotoxic to human cancer cells or xenograft tumors with mutated or epigenetically silenced BRCA1/2.2?Demonstrates antiproliferative effects in 26 out of 39 ovarian cancer cell lines.3?Synergizes with other anticancer agents such as topotecan, carboplatin, doxorubicin, paclitaxel,3 and temozolomide.4?Ameliorates the cardiotoxicity of doxorubicin.5?Recently approved for human use by the FDA.
UsesPARP inhibitor oncolytic
References1) Thomas?et al.?(2007),?Preclinical selection of a n novel poly(ADP-ribose) polymerase inhibitor for clinical trial; Mol. Cancer Ther.,?6?945 2) Drew?et al.?(2011),?Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2; J. Natl. Cancer Inst.,?103?334 3) Ihnen?et al.?(2013),?Therapeutic potential of the poly(ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer; Mol. Cancer Ther.,?12?1002 4) Plummer?et al.?(2013),?A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation; Cancer Chemother. Pharmacol.,?71?1191 5) Ali?et al.?(2011),?The clinically active PARP inhibitor AG014699 ameliorates cardiotoxicity but does not enhance the efficacy of doxorubicin, despite improving tumor perfusion and radiation response in mice; Mol. Cancer Ther.,?10?2320
PF-01367338 Preparation Products And Raw materials
NU1025 Olaparib 1H-BenziMidazole, 6-(2-chloro-5-fluoro-4-pyriMidinyl)-4-fluoro-2-Methyl-1-(1-Methylethyl)- Rapamycin 3-Aminobenzamide 4-AMINO-1,8-NAPHTHALIMIDE 4-(8-fluoro-6-oxo-3,4,5,6-tetrahydro-1H-azepino[5,4,3-cd]indol-2-yl)benzaldehyde TIQ-A Veliparib Talazoparib (BMN 673) 3-(4-CHLORO-PHENYL)-QUINOXALINE-5-CARBOXYLIC ACID AMIDE ABT-888 MK-2206 2HCl 5-((4-Ethylpiperazin-1-yl)methyl)pyridin-2-amine 2-bromo-8-fluoro-4,5-dihydro-1H-azepino[5,4,3-cd]indol-6(3H)-one 6-Bromo-4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazole 1H-BenziMidazole, 4-fluoro-2-Methyl-1-(1-Methylethyl)-6-(4,4,5,5-tetraMethyl-1,3,2-dioxaborolan-2-yl)- Everolimus

Email:[email protected] [email protected]
Copyright © 2024 Mywellwork.com All rights reserved.